Latest
Clair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable EraClair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable Era|Orthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI AgentsOrthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI Agents|Tugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era ProblemTugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era Problem|fomo Raises $75M Series B as Social Trading Moves Mainstreamfomo Raises $75M Series B as Social Trading Moves Mainstream|DropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug DiscoveryDropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug Discovery|HistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the MainstreamHistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the Mainstream|Upscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats UpUpscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats Up|Nura Bio Raises $73.8M Series B to Advance SARM1 NeuroprotectionNura Bio Raises $73.8M Series B to Advance SARM1 Neuroprotection|Vedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine TherapiesVedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine Therapies|Cargofy Raises $11M Series A as AI Workers Move From Demo to Deployment in Freight LogisticsCargofy Raises $11M Series A as AI Workers Move From Demo to Deployment in Freight Logistics|Clair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable EraClair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable Era|Orthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI AgentsOrthogonal Raises $4.3M Seed to Build the Infrastructure Layer for AI Agents|Tugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era ProblemTugboat Raises $3M Seed Round as Insurance Claims Become a Climate-Era Problem|fomo Raises $75M Series B as Social Trading Moves Mainstreamfomo Raises $75M Series B as Social Trading Moves Mainstream|DropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug DiscoveryDropGenie’s Seed+ Round Signals a New Era for Primary-Cell Drug Discovery|HistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the MainstreamHistoSonics Raises $250M in Growth Financing as Histotripsy Moves Into the Mainstream|Upscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats UpUpscale AI Raises $190M Series A at a $2B Valuation as the Battle for AI Networking Heats Up|Nura Bio Raises $73.8M Series B to Advance SARM1 NeuroprotectionNura Bio Raises $73.8M Series B to Advance SARM1 Neuroprotection|Vedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine TherapiesVedana Therapeutics Raises $46M Series A to Advance Next-Generation Migraine Therapies|Cargofy Raises $11M Series A as AI Workers Move From Demo to Deployment in Freight LogisticsCargofy Raises $11M Series A as AI Workers Move From Demo to Deployment in Freight Logistics
Back to articles
•

ParcelBio Raises $13M Seed to Advance Durable mRNA Platform for Autoimmune and Oncology Therapies

Biotech startups still walk into the room talking like they already cured mortality. Whiteboards full of arrows. Everybody promising the future of medicine while quietly praying the centrifuge stops making that noise in the corner. ParcelBio came out different. No chest pounding. No sci-fi cosplay wrapped in investor jargon. Just a San Francisco company stepping out of stealth with $13M in seed financing and a dangerous idea: what if mRNA medicines didn’t disappear before the real work starts?

That funding came from Breyer Capital, with General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, and ZAKA VC joining the round. David Weinberg, Ph.D., Co-founder and CEO, and Chris Carlson, Ph.D., Co-founder and CSO, are building ParcelBio around APEXm, short for Amplified and Prolonged EXpression mRNA. The goal: engineer mRNA medicines capable of stronger and longer-lasting protein expression without creating a manufacturing problem nobody can scale.

One of the biggest frustrations in RNA therapeutics is durability. Conventional mRNA can generate impressive expression, then fade before sustained therapeutic impact is achieved. Fine for some applications. Not ideal when targeting autoimmune disease, oncology, or therapeutic proteins where persistence changes outcomes entirely. Biology does not care how polished the investor deck looks. Cells either cooperate or they don’t.

ParcelBio’s answer is APEXm. Instead of forcing biology into submission, the platform recruits the cell’s native RNA-stabilizing machinery while maintaining a simple linear mRNA architecture. In plain English, the company is trying to make mRNA medicines more potent and durable without overengineering the system into oblivion. Scientific elegance means nothing if manufacturing, dosing windows, regulatory timelines, and economics collapse under pressure.

The pipeline shows they understand where this technology matters most. In autoimmune disease, ParcelBio is pursuing in vivo CAR-T approaches targeting pathogenic B cells with the goal of deeper immune reset and durable drug-free remission. In oncology, the platform is being developed for programmable control over potency, duration, and redosing.

The advisory bench adds credibility fast. Rachel Green, Ph.D., Stuart Milstein, Ph.D., Robbie Majzner, M.D., Megan Yung, J.D. Ph.D., and Bret Bostwick, M.D. bring expertise spanning RNA biology, CAR-T therapy, translational medicine, and biotech commercialization.

The mRNA sector got loud after 2020. Every company suddenly sounded revolutionary. ParcelBio feels more disciplined than theatrical. Less obsession with speed alone. More focus on durability, controllability, and therapeutic thresholds existing mRNA platforms still struggle to reach. In biotech, the difference between a breakthrough and a science project usually comes down to whether the medicine lasts long enough to matter.

ParcelBio

ParcelBio

  • San Francisco
WebsiteLinkedIn

Key Executives

  • David Weinberg
  • Ph.D. (Co-founder and CEO)
+12 more (coming soon)

Investors

Breyer Capital

Related Articles

Trending

View all posts